C12N 2710/16133
Use of viral protein as therapeutic agent other than vaccine
Official title: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/16133 (Use of viral protein as therapeutic agent other than vaccine) appears on 9 US grants and 14 published applications in this corpus.
Search patents in C12N- Granted patents
- 9
- Published applications
- 14
- Assignees
- 12
- Inventors
- 31
- Latest grant
- 6 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 0 | 1 |
| 2014 | 1 | 1 |
| 2015 | 0 | 2 |
| 2016 | 2 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 1 | 2 |
| 2020 | 0 | 2 |
| 2021 | 1 | 0 |
| 2022 | 1 | 1 |
| 2023 | 0 | 2 |
| 2024 | 2 | 1 |
| 2025 | 0 | 0 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for treating HIV infection and reversing HIV latency6 Jan 2026US 12,514,921 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- FcRn-targeted therapeutics for the treatment of antibody-mediated autoimmune and albumin-mediated disease1 Oct 2024US 12,102,679 B2University of Maryland, College Park
- T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof11 Jun 2024US 12,006,348 B2Cue Biopharma, Inc.
- FcRn-targeted therapeutics for the treatment of antibody-mediated autoimmune and albumin-mediated disease18 Oct 2022US 11,471,526 B2University of Maryland, College Park
- Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients30 Nov 2021US 11,186,824 B2Cellectis
- T-Cell Modulatory Multimeric Polypeptide with Conjugation Sites and Methods of Use Thereof12 Dec 2024US 2024/0409606 A1Cue Biopharma, Inc.
- Methods for treating and preventing cytomegalovirus infection21 Sep 2023US 2023/0293673 A1Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
- Fcrn-targeted therapeutics for the treatment of antibody-mediated autoimmune and albumin-mediated disease15 Jun 2023US 2023/0181723 A1University of Maryland, College Park
- Compositions and methods for detecting hiv latency, treating hiv infection, and reversing hiv latency11 Aug 2022US 2022/0249653 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- T-Cell Modulatory Multimeric Polypeptide with Conjugation Sites and Methods of Use Thereof26 Nov 2020US 2020/0369745 A1Cue Biopharma, Inc.
Most cited
By later US patents
- Disulfide-linked multivalent MHC class I comprising multi-function proteins30US 10,501,521 B2Hoffmann-La Roche Inc. · 2019
- Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients3US 11,186,824 B2Cellectis · 2021
- Peptide compositions and methods for inhibiting herpesvirus infection1US 8,802,106 B2The Administrators of the Tulane Educational Fund · 2014
- Peptide compositions and methods for inhibiting herpesvirus infection1US 9,434,769 B2The Administrators of the Tulane Educational Fund · 2016